{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:59:16Z","timestamp":1794513556745,"version":"4.9.1"},"reference-count":212,"publisher":"Oxford University Press (OUP)","issue":"27","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French National Research Agency Fighting Heart Failure"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment-resistant hypertension (TRH) often coexists with chronic kidney disease (CKD), and the presence of both conditions increases the risk of adverse cardiovascular outcomes. Patients with TRH and CKD exhibit enhanced aldosterone and mineralocorticoid receptor expression, which promote inflammation and fibrosis in cardiac and renal tissues, contributing to the development and progression of cardiorenal diseases. Both achieving optimal blood pressure (BP) control and mitigating the risk of aldosterone-related adverse events are cornerstones in the management of patients with TRH and CKD. Mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of TRH. To date, the efficacy has been investigated in populations with mostly normal renal function. However, the potential risk of hyperkalaemia limits the use of MRAs, particularly in patients with CKD. Non-steroidal MRAs and sodium glucose cotransporter-2 inhibitors have slowed renal function decline and shown cardiorenal benefits. Additionally, aldosterone synthase inhibitors may emerge as a therapeutic option for patients with TRH. Clinical trials for TRH primarily centred on assessing BP-lowering effects; however, merely lowering BP might not be a sufficient target to prevent a risk of cardiorenal disease progression. This paper presents evidence and potential benefits of aldosterone-targeted therapy in the treatment of TRH and CKD and re-consider the treatment strategies in clinical practice and trial design.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf225","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T11:35:58Z","timestamp":1743248158000},"page":"2618-2642","source":"Crossref","is-referenced-by-count":48,"title":["Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-2256","authenticated-orcid":false,"given":"Masatake","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network , Nancy ,","place":["France"]},{"name":"Department of Cardiology, Tokyo Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network , Nancy ,","place":["France"]},{"name":"Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Cardiovascular Research and Development Center , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-7932","authenticated-orcid":false,"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network , Nancy ,","place":["France"]},{"name":"ALTIR , Nancy ,","place":["France"]},{"name":"Medical Specialties and Nephrology Dialysis Departments, Monaco Princess Grace Hospital and Monaco Private Hemodialysis Centre , Monaco ,","place":["Monaco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-2057","authenticated-orcid":false,"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2025071406514621600_ehaf225-B1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B2","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/eurheartj\/ehad299","article-title":"Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade","volume":"45","author":"Pitt","year":"2023","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B5","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tcm.2021.04.003","article-title":"Editorial commentary: adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism","volume":"32","author":"Ruilope","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"2025071406514621600_ehaf225-B7","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.121.17436","article-title":"Renal injuries in primary aldosteronism: quantitative histopathological analysis of 19 patients with primary adosteronism","volume":"78","author":"Ogata","year":"2021","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"2025071406514621600_ehaf225-B10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025071406514621600_ehaf225-B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B15","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B16","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41371-022-00701-0","article-title":"Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study","volume":"37","author":"Mielke","year":"2023","journal-title":"J Hum Hypertens"},{"key":"2025071406514621600_ehaf225-B19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10157-022-02250-9","article-title":"Current antihypertensive treatment and treatment-resistant hypertension in Japanese patients with chronic kidney disease","volume":"26","author":"Tsuchimoto","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"2025071406514621600_ehaf225-B21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse north American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025071406514621600_ehaf225-B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"2025071406514621600_ehaf225-B23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"2025071406514621600_ehaf225-B25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.ajkd.2013.11.016","article-title":"Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study","volume":"63","author":"Tanner","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025071406514621600_ehaf225-B26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.115.05694","article-title":"Prevalence of apparent therapy-resistant hypertension and its effect on outcome in patients with chronic kidney disease","volume":"66","author":"de Beus","year":"2015","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B28","first-page":"386","article-title":"Stimulation of aldosterone secretion by angiotensisn. II. A preliminary report","volume":"33","author":"Mulrow","year":"1961","journal-title":"Yale J Biol Med"},{"key":"2025071406514621600_ehaf225-B29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1210\/endo-58-1-104","article-title":"The effect of corticosteroid injection on aldosterone secretion","volume":"58","author":"Farrell","year":"1956","journal-title":"Endocrinology"},{"key":"2025071406514621600_ehaf225-B30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2025071406514621600_ehaf225-B31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00424-009-0656-0","article-title":"Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC)","volume":"458","author":"Loffing","year":"2009","journal-title":"Pflugers Arch"},{"key":"2025071406514621600_ehaf225-B32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","article-title":"Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity","volume":"48","author":"Nagata","year":"2006","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat Med"},{"key":"2025071406514621600_ehaf225-B34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"2025071406514621600_ehaf225-B35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejphar.2016.05.030","article-title":"Roles of aldosterone in vascular calcification: an update","volume":"786","author":"Gao","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"2025071406514621600_ehaf225-B36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025071406514621600_ehaf225-B37","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"2025071406514621600_ehaf225-B38","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B39","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"2025071406514621600_ehaf225-B40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025071406514621600_ehaf225-B41","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/sj.ki.5000201","article-title":"Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury","volume":"69","author":"Ma","year":"2006","journal-title":"Kidney Int"},{"key":"2025071406514621600_ehaf225-B42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh","year":"2012","journal-title":"J Cell Physiol"},{"key":"2025071406514621600_ehaf225-B43","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B44","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1681\/ASN.2006080944","article-title":"Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors","volume":"17","author":"Nagase","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B45","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/HYPERTENSIONAHA.114.01997","article-title":"Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction","volume":"63","author":"Jaffe","year":"2014","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01.mnh.0000133976.32559.b0","article-title":"Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension","volume":"13","author":"Frey","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025071406514621600_ehaf225-B47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025071406514621600_ehaf225-B48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/HYPERTENSIONAHA.114.04117","article-title":"Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome","volume":"65","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025071406514621600_ehaf225-B50","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"2025071406514621600_ehaf225-B52","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"2025071406514621600_ehaf225-B53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2025071406514621600_ehaf225-B54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nrneph.2012.282","article-title":"Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease","volume":"9","author":"Nagase","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025071406514621600_ehaf225-B55","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B56","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B60","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025071406514621600_ehaf225-B62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans : a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025071406514621600_ehaf225-B63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/HYPERTENSIONAHA.120.15950","article-title":"Masked uncontrolled hypertension is accompanied by increased out-of-clinic aldosterone secretion","volume":"77","author":"Siddiqui","year":"2021","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B64","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B65","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B66","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"key":"2025071406514621600_ehaf225-B68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025071406514621600_ehaf225-B69","doi-asserted-by":"publisher","first-page":"e185842","DOI":"10.1001\/jamasurg.2018.5842","article-title":"Clinical outcomes after unilateral adrenalectomy for primary aldosteronism","volume":"154","author":"Vorselaars","year":"2019","journal-title":"JAMA Surg"},{"key":"2025071406514621600_ehaf225-B70","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1161\/HYPERTENSIONAHA.119.13463","article-title":"Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling","volume":"74","author":"Rossi","year":"2019","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B71","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1161\/HYPERTENSIONAHA.123.21474","article-title":"Primary aldosteronism in chronic kidney disease: blood pressure control and kidney and cardiovascular outcomes after surgical versus medical management","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B72","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.0197-3118.2006.05470.x","article-title":"Cardiometabolic syndrome and chronic kidney disease: what is the link?","volume":"1","author":"Sarafidis","year":"2006","journal-title":"J Cardiometab Syndr"},{"key":"2025071406514621600_ehaf225-B74","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B75","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(14)60155-0","article-title":"Chronic kidney disease and the ageing population","volume":"383","author":"Tonelli","year":"2014","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B76","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/HYPERTENSIONAHA.122.19213","article-title":"Mechanism by which inflammation and oxidative stress induce mineralocorticoid receptor gene expression in aging vascular smooth muscle cells","volume":"80","author":"Ibarrola","year":"2023","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B77","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1161\/HYPERTENSIONAHA.117.10437","article-title":"Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging","volume":"71","author":"Kim","year":"2018","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B78","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B79","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1001\/archinte.165.18.2098","article-title":"Racial disparities in hypertension prevalence, awareness, and management","volume":"165","author":"Hertz","year":"2005","journal-title":"Arch Intern Med"},{"key":"2025071406514621600_ehaf225-B80","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.ajkd.2013.03.009","article-title":"Lifetime incidence of CKD stages 3\u20135 in the United States","volume":"62","author":"Grams","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025071406514621600_ehaf225-B81","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2017.01.040","article-title":"Apolipoprotein L1 variants and blood pressure traits in African Americans","volume":"69","author":"Nadkarni","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B82","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2018.13467","article-title":"Association of clinical and social factors with excess hypertension risk in black compared with white US adults","volume":"320","author":"Howard","year":"2018","journal-title":"JAMA"},{"key":"2025071406514621600_ehaf225-B83","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.ajkd.2018.06.021","article-title":"Kidney disease among African Americans: a population perspective","volume":"72","author":"Laster","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2025071406514621600_ehaf225-B84","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.118.11064","article-title":"Hypertension in blacks: individualized therapy based on renin\/aldosterone phenotyping","volume":"72","author":"Spence","year":"2018","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B85","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: the Jackson heart study","volume":"143","author":"Joseph","year":"2021","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B86","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B87","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/HJH.0b013e328353634e","article-title":"Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs","volume":"30","author":"de la Sierra","year":"2012","journal-title":"J Hypertens"},{"key":"2025071406514621600_ehaf225-B88","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"key":"2025071406514621600_ehaf225-B89","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrneph.2016.191","article-title":"Kidney disease and obesity: epidemiology, mechanisms and treatment","volume":"13","author":"C\u00e2mara","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025071406514621600_ehaf225-B90","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cellsig.2017.08.004","article-title":"In situ detection of the activation of Rac1 and RalA small GTPases in mouse adipocytes by immunofluorescent microscopy following in vivo and ex vivo insulin stimulation","volume":"39","author":"Takenaka","year":"2017","journal-title":"Cell Signal"},{"key":"2025071406514621600_ehaf225-B92","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003\u20132008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B93","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","article-title":"Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system","volume":"88","author":"Sim","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2025071406514621600_ehaf225-B94","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/jch.12410","article-title":"Resistant hypertension and associated comorbidities in a veterans affairs population","volume":"16","author":"Acharya","year":"2014","journal-title":"J Clin Hypertension (Greenwich)"},{"key":"2025071406514621600_ehaf225-B95","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B96","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"2025071406514621600_ehaf225-B97","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1210\/en.2003-1137","article-title":"Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C","volume":"145","author":"Mihailidou","year":"2004","journal-title":"Endocrinology"},{"key":"2025071406514621600_ehaf225-B98","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/01.ATV.0000155325.41507.e0","article-title":"Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance","volume":"25","author":"Rask-Madsen","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025071406514621600_ehaf225-B99","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2025071406514621600_ehaf225-B100","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B101","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025071406514621600_ehaf225-B102","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B103","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2025071406514621600_ehaf225-B104","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/13543784.2021.1985462","article-title":"An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension","volume":"30","author":"Pitt","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2025071406514621600_ehaf225-B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.16966\/2470-1009.137","article-title":"Pharmacological profile of KBP-5074, a novel NonSteroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases","volume":"3","author":"Chow","year":"2017","journal-title":"J Drug Res Dev"},{"key":"2025071406514621600_ehaf225-B106","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","article-title":"Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects","volume":"84","author":"Kato","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025071406514621600_ehaf225-B107","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","article-title":"Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice","volume":"42","author":"Bhuiyan","year":"2019","journal-title":"Hypertension Res"},{"key":"2025071406514621600_ehaf225-B108","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"key":"2025071406514621600_ehaf225-B109","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"V\u00e1clav\u00edk","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025071406514621600_ehaf225-B110","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"J Clin Hypertension (Greenwich)"},{"key":"2025071406514621600_ehaf225-B111","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"2025071406514621600_ehaf225-B112","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2025071406514621600_ehaf225-B113","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","article-title":"The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio","volume":"116","author":"Hood","year":"2007","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B114","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025071406514621600_ehaf225-B115","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/HJH.0000000000001264","article-title":"Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension","volume":"35","author":"Schneider","year":"2017","journal-title":"J Hypertens"},{"key":"2025071406514621600_ehaf225-B116","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"2025071406514621600_ehaf225-B117","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"2025071406514621600_ehaf225-B118","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2025071406514621600_ehaf225-B119","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B120","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clinical Kidney J"},{"key":"2025071406514621600_ehaf225-B121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B122","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B123","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2025071406514621600_ehaf225-B124","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ehjcvp\/pvab031","article-title":"Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial","volume":"8","author":"Ferreira","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025071406514621600_ehaf225-B125","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of resistant and refractory hypertension","volume":"124","author":"Acelajado","year":"2019","journal-title":"Circ Res"},{"key":"2025071406514621600_ehaf225-B126","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B127","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"2025071406514621600_ehaf225-B128","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008996.pub2","article-title":"Eplerenone for hypertension","volume":"2","author":"Tam","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025071406514621600_ehaf225-B129","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"2025071406514621600_ehaf225-B130","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B131","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial","volume":"76","author":"Bakris","year":"2020","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B132","author":"NORDISK N"},{"key":"2025071406514621600_ehaf225-B133","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B134","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B135","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B136","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B137","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025071406514621600_ehaf225-B138","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B139","doi-asserted-by":"publisher","first-page":"Cd007004","DOI":"10.1002\/14651858.CD007004.pub4","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025071406514621600_ehaf225-B140","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025071406514621600_ehaf225-B141","doi-asserted-by":"publisher","first-page":"101190","DOI":"10.1016\/j.diabet.2020.08.005","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial","volume":"47","author":"Brandt-Jacobsen","year":"2021","journal-title":"Diabetes Metab"},{"key":"2025071406514621600_ehaf225-B142","doi-asserted-by":"publisher","first-page":"e005288","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2025071406514621600_ehaf225-B143","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B144","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2025071406514621600_ehaf225-B145","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B146","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s00392-022-02116-w","article-title":"Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial","volume":"112","author":"Ferreira","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2025071406514621600_ehaf225-B147","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B148","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2025071406514621600_ehaf225-B149","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"2025071406514621600_ehaf225-B150","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"2025071406514621600_ehaf225-B151","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025071406514621600_ehaf225-B152","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B153","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B154","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B155","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B156","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","article-title":"Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs","volume":"10","author":"Ferreira","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025071406514621600_ehaf225-B157","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.jacc.2024.03.426","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function","volume":"83","author":"Matsumoto","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B158","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025071406514621600_ehaf225-B159","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B160","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B161","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B162","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study","volume":"33","author":"Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025071406514621600_ehaf225-B163","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2025071406514621600_ehaf225-B164","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025071406514621600_ehaf225-B165","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B166","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/ckj\/sfad090","article-title":"Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!","volume":"16","author":"Rossignol","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025071406514621600_ehaf225-B167","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B168","doi-asserted-by":"publisher","first-page":"e13413","DOI":"10.1111\/ijcp.13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: a meta-analysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"key":"2025071406514621600_ehaf225-B169","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B170","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B171","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B172","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/HCO.0000000000000188","article-title":"Thiazides in advanced chronic kidney disease: time for a randomized controlled trial","volume":"30","author":"Sinha","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"2025071406514621600_ehaf225-B173","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000358603","article-title":"Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study","volume":"39","author":"Agarwal","year":"2014","journal-title":"Am J Nephrol"},{"key":"2025071406514621600_ehaf225-B174","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B175","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/HYPERTENSIONAHA.123.21962","article-title":"Chlorthalidone or spironolactone for patients with TRH and advanced chronic kidney disease?","volume":"81","author":"Pitt","year":"2023","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B176","doi-asserted-by":"publisher","first-page":"1229.e1","DOI":"10.1016\/j.amjmed.2012.05.023","article-title":"Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil","volume":"125","author":"Bakris","year":"2012","journal-title":"Am J Med"},{"key":"2025071406514621600_ehaf225-B177","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B178","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events","volume":"387","author":"Ishani","year":"2022","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B179","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B180","doi-asserted-by":"publisher","first-page":"Pl45","DOI":"10.1016\/s0024-3205(98)00265-3","article-title":"Torsemide inhibits aldosterone secretion in vitro","volume":"63","author":"Goodfriend","year":"1998","journal-title":"Life Sci"},{"key":"2025071406514621600_ehaf225-B181","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11906-023-01281-1","article-title":"Blood pressure effects of SGLT2 inhibitors: mechanisms and clinical evidence in different populations","volume":"25","author":"Beal","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"2025071406514621600_ehaf225-B182","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B183","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2025071406514621600_ehaf225-B184","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B185","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B186","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B187","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2024","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B188","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025071406514621600_ehaf225-B189","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MED.0b013e328360c200","article-title":"Evolving research in nongenomic actions of aldosterone","volume":"20","author":"Williams","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2025071406514621600_ehaf225-B190","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"J Vasc Res"},{"key":"2025071406514621600_ehaf225-B191","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","article-title":"Inhibitors of aldosterone synthase","volume":"109","author":"Weldon","year":"2019","journal-title":"Vitam Horm"},{"key":"2025071406514621600_ehaf225-B192","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B193","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJMe2216143","article-title":"Decreasing the effects of aldosterone in resistant hypertension - a success story","volume":"388","author":"Azizi","year":"2023","journal-title":"N Engl J Med"},{"key":"2025071406514621600_ehaf225-B194","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/HYPERTENSIONAHA.112.196113","article-title":"Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase","volume":"60","author":"L\u00f3pez","year":"2012","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B195","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am J Cardiol"},{"key":"2025071406514621600_ehaf225-B196","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/ndt\/12.9.1883","article-title":"Urinary and serum type III collagen: markers of renal fibrosis","volume":"12","author":"Soylemezoglu","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2025071406514621600_ehaf225-B197","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B198","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B199","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ejhf.1812","article-title":"Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and\/or heart failure","volume":"22","author":"Stienen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B200","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2025071406514621600_ehaf225-B201","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ejhf.2579","article-title":"The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial","volume":"24","author":"Kobayashi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025071406514621600_ehaf225-B202","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2023.01.088","article-title":"Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials","volume":"377","author":"Ferreira","year":"2023","journal-title":"Int J Cardiol"},{"key":"2025071406514621600_ehaf225-B203","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/HYPERTENSIONAHA.112.196410","article-title":"Failure to downregulate the epithelial sodium channel causes salt sensitivity in Hsd11b2 heterozygote mice","volume":"60","author":"Craigie","year":"2012","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B204","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B205","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B206","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/HYPERTENSIONAHA.114.04852","article-title":"Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial","volume":"65","author":"Muxfeldt","year":"2015","journal-title":"Hypertension"},{"key":"2025071406514621600_ehaf225-B207","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(22)01787-1","article-title":"Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 trial","volume":"400","author":"Bhatt","year":"2022","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B208","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B209","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"2025071406514621600_ehaf225-B210","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025071406514621600_ehaf225-B211","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.120.049514","article-title":"Challenges of cardio-kidney composite outcomes in large-scale clinical trials","volume":"143","author":"Patel","year":"2021","journal-title":"Circulation"},{"key":"2025071406514621600_ehaf225-B212","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/27\/2618\/62915869\/ehaf225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/27\/2618\/62915869\/ehaf225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T10:51:54Z","timestamp":1752490314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/27\/2618\/8111531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":212,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2025,4,11]]},"published-print":{"date-parts":[[2025,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf225","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,14]]},"published":{"date-parts":[[2025,4,11]]}}}